Navigation Links
AFFiRiS AG - Encouraging Results From Phase I Studies of two Alzheimer's Candidate Vaccines Trigger a EUR 10 Million Milestone Payment
Date:10/20/2009

VIENNA, Austria, October 20 /PRNewswire/ -- AFFiRiS AG today announced that the primary endpoints have been met for the Phase I clinical studies of its two Alzheimer's vaccines AD01 and AD02, which demonstrated favourable safety and tolerability profiles. These results trigger a 10 million EUR milestone payment from licensee GlaxoSmithKline Biologicals.

All 48 patients treated in these studies were given four vaccinations which were well tolerated and no serious side effects associated with the vaccine candidates were observed.

The results demonstrate the potential value of the AFFITOME(R) technology, which forms the platform for both of these vaccines and could result in a generation of highly specific vaccines. While analysing the clinical outcome in detail the company, together with GSK Biologicals is progressing to the next development stage. AFFiRiS AG is also using AFFITOME(R) technology to develop vaccines for Parkinson's disease, atherosclerosis and four other indications.

Affinity to Success

Commenting on the results, AFFiRiS' CEO, Dr. Walter Schmidt, said: "This initial demonstration of safety and tolerability is an outstanding milestone in our joint efforts with GSK Biologicals to develop a therapeutic Alzheimer's vaccination. However, the results also highlight the potential capability of our AFFITOME(R) technology, which forms the basis for the two vaccine candidates. This technology is also the platform for our six other vaccine programmes, including Parkinson's and atherosclerosis currently under development. The results not only represent an important milestone in the development of our Alzheimer's vaccination but also confirm our basic strategy. We will be investing all of this milestone payment in our research and development projects."

In October 2008 AFFiRiS concluded a licensing agreement with GSK Biologicals on jointly developing the Alzheimer's vaccines AD01 and AD02. Comprising total payments of up to EUR 430 million upon successful commercialisation, and the progress that has now been achieved is a key milestone in the collaboration. As part of this agreement, GSK Biologicals has gained access to the AFFITOME(R) technology of AFFiRiS, in the field of Alzheimer vaccination.

In other indications AFFiRiS retains the exclusive rights to this technology. In summary, the AFFITOME(R) technology delivers short synthetic peptides that mimic functionally highly specific original structures such as those of antigens. This can be used to generate vaccines - particularly important with Alzheimer's vaccines - that lead to the formation of antibodies which target only detrimental derivatives of human proteins and leaving their healthy precursor forms alone.

Success for Both Vaccine Candidates

The clinical studies to test the two therapeutic Alzheimer's vaccines were conducted in Vienna, Austria, using two different peptide antigens. 24 patients with mild to moderate stage of the disease were recruited for each of the two studies. Each patient received four vaccinations at four-weekly intervals. Both groups were divided into two subgroups of 12 patients who received the vaccine with or without an adjuvant. Commenting on the results, Dr. Frank Mattner, CSO of AFFiRiS AG, said: "All 48 patients were able to complete the study without any problems, with the data now evaluated demonstrating acceptable tolerability of vaccine candidates AD01 and AD02. None of the 48 participants in the studies showed any indications of meningoencephalitis or other autoimmune reactions that have caused severe problems for other Alzheimer's vaccine candidates. We are now analysing the immunological data and results of the cognitive tests in detail."

AFFiRiS AG (as at October 2009):

Based on its proprietary patent position AFFiRiS AG develops tailor-made peptide-vaccines against Alzheimer's, Atherosclerosis, Parkinson's and another four diseases with unmet medical need and attractive markets. Alzheimer's disease is currently the lead indication and recently two vaccine candidates have completed the phase I clinical testing. In October 2008, the company closed a licensing deal with GlaxoSmithKline Biologicals on its Alzheimer's vaccine program. The contract foresees payments of up to EUR 430 million. AFFiRiS currently has 60 highly-qualified employees and recently extended its facilities at the Campus Vienna Biocenter, Austria, up to 1,700 square meters (http://www.affiris.com).

    Contact at AFFiRiS AG:

    Agnes Meyer
    Karl-Farkas-Gasse 22
    1030 Vienna
    Austria
    T +43-1-798-15-75-39
    E agnes.meyer@affiris.com
    W http://www.affiris.com

    Copy Editing & Distribution:

    PR&D - Public Relations for
    Research & Education
    Campus Vienna Biocenter 2
    1030 Vienna
    Austria
    T +43-1-505-70-44
    E contact@prd.at
    W http://www.prd.at

SOURCE AFFiRis AG


'/>"/>
SOURCE AFFiRis AG
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. AFFiRiS Begins Development of a Parkinsons Vaccine
2. AFFiRiS: Milestone Reached in Clinical Trial of Alzheimers Vaccine
3. NKTR-102 Shows Encouraging Anti-Tumor Activity in Ovarian Cancer in Phase 1 and Preclinical Data Presented at the ECCO 15 and 34th ESMO Multidisciplinary Congress
4. Encouraging First Data on New Targeted Treatment for Patients With Melanoma - the Deadliest Form of Skin Cancer
5. Following Encouraging Results Anthera to Continue IMPACTS Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
6. Encouraging Gene Therapy Results in Genetic Form of Blindness
7. Exelixis Reports Encouraging Phase 1 Data for XL184 at ASCO
8. Aeras, Crucell and South African Tuberculosis Vaccine Initiative Announce Encouraging Preliminary Results of Tuberculosis Vaccine Clinical Trial in South Africa
9. PTC Therapeutics Presents Encouraging Phase 1 Results of its Novel VEGF Inhibitor, PTC299, at 30th Annual San Antonio Breast Cancer Symposium
10. Exelixis Presents Encouraging Phase 1 Data For XL019, A Novel Selective Inhibitor of JAK2
11. New UNAIDS Report Offers Encouraging News, But Most HIV-Positive Mothers Still Not Getting the Care & Treatment They Need
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2017)... DIEGO , Sept. 22, 2017 AVACEN ... medical device is now successfully helping those with the ... Fibromyalgia diagnosed Amanda in Essex, ... dressed and washing my hair, experiencing no sleep at ... in painful spasm… I cannot recommend [the AVACEN 100] ...
(Date:9/18/2017)... 18, 2017 EpiVax, Inc. ("EpiVax") ... and immune engineering, today announced a new ... (H7N9) vaccine. ... influenza and presents a challenge for traditional ... to be effective. Using state-of-the-art bioinformatics and molecular ...
(Date:9/12/2017)...  ValGenesis Inc., the global leader in Enterprise ... announce the appointment of Dr. Ajaz Hussain ... Directors and Chairman of Advisory Board beginning September ... to manage their entire validation lifecycle process electronically ... process. Furthermore, ValGenesis VLMS enables rigorous compliance, helps ...
Breaking Medicine Technology:
(Date:10/12/2017)... Francisco, CA (PRWEB) , ... October 12, 2017 ... ... Dr. Cheng, are now treating sleep apnea using cutting-edge Oventus O2Vent ... apnea, a serious sleep disorder characterized by frequent cessation in breathing. Oral appliances ...
(Date:10/12/2017)... ... October 12, 2017 , ... The ... demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, ... to meet the highest standard. , These products are also: Gluten Free, ...
(Date:10/12/2017)... ... ... The American College of Medical Informatics (ACMI) will present the 2017 Morris ... of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium is taking ... in the field of medical informatics, this prestigious award is presented to an individual ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... drug delivery system that we intend to develop to enable prevention of a ... lead to severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader in ... 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were announced ... 2017. , The annual award competition recognizes editorial and design excellence across a range ...
Breaking Medicine News(10 mins):